 bcl-X Protein
"bcl-X Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A member of the bcl-2 protein family that plays a role in the regulation of APOPTOSIS. Two major isoforms of the protein exist due to ALTERNATIVE SPLICING of the BCL2L1 mRNA and are referred to as Bcl-XS and Bcl-XL.
| Descriptor ID |
D051020
|
| MeSH Number(s) |
D12.644.360.075.718.937 D12.776.476.075.718.875
|
| Concept/Terms |
bcl-X Protein- bcl-X Protein
- bcl X Protein
- bcl2L1 Protein
- bcl2-Like 1 Protein
- bcl2 Like 1 Protein
bcl-Xbeta Protein- bcl-Xbeta Protein
- bcl Xbeta Protein
- bcl-Xb Protein
- bcl Xb Protein
- bcl-x(beta) Protein
bcl-XS Protein- bcl-XS Protein
- bcl XS Protein
- bcl-Xshort Protein
- bcl Xshort Protein
- bcl-X(S) Protein
bcl-XL Protein- bcl-XL Protein
- bcl XL Protein
- bcl-Xlong Protein
- bcl Xlong Protein
- bcl-X(L) Protein
|
Below are MeSH descriptors whose meaning is more general than "bcl-X Protein".
Below are MeSH descriptors whose meaning is more specific than "bcl-X Protein".
This graph shows the total number of publications written about "bcl-X Protein" by people in UAMS Profiles by year, and whether "bcl-X Protein" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 0 | 2 | 2 | | 2023 | 0 | 1 | 1 | | 2022 | 0 | 2 | 2 | | 2021 | 3 | 1 | 4 | | 2020 | 3 | 1 | 4 | | 2019 | 2 | 0 | 2 | | 2017 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 | | 2015 | 0 | 2 | 2 | | 2014 | 1 | 0 | 1 | | 2013 | 2 | 2 | 4 | | 2012 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2010 | 0 | 2 | 2 | | 2009 | 2 | 0 | 2 | | 2008 | 1 | 1 | 2 | | 2007 | 1 | 1 | 2 | | 2006 | 1 | 1 | 2 | | 2005 | 0 | 4 | 4 | | 2004 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "bcl-X Protein" by people in Profiles over the past ten years.
-
Nayak D, Lv D, Yuan Y, Zhang P, Hu W, Nayak A, Ruben EA, Lv Z, Sung P, Hromas R, Zheng G, Zhou D, Olsen SK. Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL. Nat Commun. 2024 Mar 29; 15(1):2743.
-
Khan S, Cao L, Wiegand J, Zhang P, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D. PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. Cells. 2024 Mar 17; 13(6).
-
Jia Y, Han L, Ramage CL, Wang Z, Weng CC, Yang L, Colla S, Ma H, Zhang W, Andreeff M, Daver N, Jain N, Pemmaraju N, Bhalla K, Mustjoki S, Zhang P, Zheng G, Zhou D, Zhang Q, Konopleva M. Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells. Haematologica. 2023 10 01; 108(10):2626-2638.
-
Jaiswal A, Jaiswal A, Williamson EA, Gelfond J, Zheng G, Zhou D, Hromas R. Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis. Cancer Chemother Pharmacol. 2023 01; 91(1):89-95.
-
Khan S, Wiegand J, Zhang P, Hu W, Thummuri D, Budamagunta V, Hua N, Jin L, Allegra CJ, Kopetz SE, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D. BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. J Hematol Oncol. 2022 03 09; 15(1):23.
-
Lv D, Pal P, Liu X, Jia Y, Thummuri D, Zhang P, Hu W, Pei J, Zhang Q, Zhou S, Khan S, Zhang X, Hua N, Yang Q, Arango S, Zhang W, Nayak D, Olsen SK, Weintraub ST, Hromas R, Konopleva M, Yuan Y, Zheng G, Zhou D. Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nat Commun. 2021 11 25; 12(1):6896.
-
Thummuri D, Khan S, Underwood PW, Zhang P, Wiegand J, Zhang X, Budamagunta V, Sobh A, Tagmount A, Loguinov A, Riner AN, Akki AS, Williamson E, Hromas R, Vulpe CD, Zheng G, Trevino JG, Zhou D. Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-XL-Specific Degrader DT2216. Mol Cancer Ther. 2022 01; 21(1):184-192.
-
Pal P, Thummuri D, Lv D, Liu X, Zhang P, Hu W, Poddar SK, Hua N, Khan S, Yuan Y, Zhang X, Zhou D, Zheng G. Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition. J Med Chem. 2021 10 14; 64(19):14230-14246.
-
Kolb R, De U, Khan S, Luo Y, Kim MC, Yu H, Wu C, Mo J, Zhang X, Zhang P, Zhang X, Borcherding N, Koppel D, Fu YX, Zheng SG, Avram D, Zheng G, Zhou D, Zhang W. Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nat Commun. 2021 02 24; 12(1):1281.
-
He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, Thummuri D, Ortiz YT, Zhang X, Lv D, Wiegand JS, Li W, Palmer AC, Zheng G, Weinstock DM, Zhou D. DT2216-a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas. J Hematol Oncol. 2020 07 16; 13(1):95.
-
Zhang X, He Y, Zhang P, Budamagunta V, Lv D, Thummuri D, Yang Y, Pei J, Yuan Y, Zhou D, Zheng G. Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines. Eur J Med Chem. 2020 Aug 01; 199:112397.
-
He Y, Zhang X, Chang J, Kim HN, Zhang P, Wang Y, Khan S, Liu X, Zhang X, Lv D, Song L, Li W, Thummuri D, Yuan Y, Wiegand JS, Ortiz YT, Budamagunta V, Elisseeff JH, Campisi J, Almeida M, Zheng G, Zhou D. Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity. Nat Commun. 2020 04 24; 11(1):1996.
-
Zhang X, Thummuri D, Liu X, Hu W, Zhang P, Khan S, Yuan Y, Zhou D, Zheng G. Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity. Eur J Med Chem. 2020 Apr 15; 192:112186.
-
Zhang X, Thummuri D, He Y, Liu X, Zhang P, Zhou D, Zheng G. Utilizing PROTAC technology to address the on-target platelet toxicity associated with inhibition of BCL-XL. Chem Commun (Camb). 2019 Dec 05; 55(98):14765-14768.
-
Khan S, Zhang X, Lv D, Zhang Q, He Y, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand JS, Pei J, Zhang W, Sharma A, McCurdy CR, Kuruvilla VM, Baran N, Ferrando AA, Kim YM, Rogojina A, Houghton PJ, Huang G, Hromas R, Konopleva M, Zheng G, Zhou D. A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. 2019 12; 25(12):1938-1947.
-
Wu X, Zhang LS, Toombs J, Kuo YC, Piazza JT, Tuladhar R, Barrett Q, Fan CW, Zhang X, Walensky LD, Kool M, Cheng SY, Brekken R, Opferman JT, Green DR, Moldoveanu T, Lum L. Extra-mitochondrial prosurvival BCL-2 proteins regulate gene transcription by inhibiting the SUFU?tumour suppressor. Nat Cell Biol. 2017 Oct; 19(10):1226-1236.
-
Lee T, Bian Z, Zhao B, Hogdal LJ, Sensintaffar JL, Goodwin CM, Belmar J, Shaw S, Tarr JC, Veerasamy N, Matulis SM, Koss B, Fischer MA, Arnold AL, Camper DV, Browning CF, Rossanese OW, Budhraja A, Opferman J, Boise LH, Savona MR, Letai A, Olejniczak ET, Fesik SW. Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitors. FEBS Lett. 2017 Jan; 591(1):240-251.
-
Chang J, Wang Y, Shao L, Laberge RM, Demaria M, Campisi J, Janakiraman K, Sharpless NE, Ding S, Feng W, Luo Y, Wang X, Aykin-Burns N, Krager K, Ponnappan U, Hauer-Jensen M, Meng A, Zhou D. Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med. 2016 Jan; 22(1):78-83.
-
Zheng JH, Viacava Follis A, Kriwacki RW, Moldoveanu T. Discoveries and controversies in BCL-2 protein-mediated apoptosis. FEBS J. 2016 07; 283(14):2690-700.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|